The N-glycolylated variant of ganglioside GM3 in tumor biology: An attractive target for cancer immunotherapy;La variante N-glcolilada del gangliósldo GM3 en la biología de los tumores: Un bianco atractivo para la inmunoterapia del cáncer

Biotecnologia Aplicada

Volumn 25, Issue 2, 2008, Pages 161-170

  De León, Joel ^a   Fernández, Audry ^a   Clavell, Marilyn ^a   López, Armando ^a   Labrada, Mayrel ^a   Bebelagua, Yanin ^a   Mesa, Circe ^a   Fernández, Luis E ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; N GLYCOLYL GANGLIOSIDE GM3; SPHINGOLIPID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BAGG ALBINO MOUSE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MEMBRANE; CELL PROLIFERATION; CYTOKINE RELEASE; DENDRITIC CELL; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR GROWTH;

EID: 61449131393     PISSN: 08644551     EISSN: 10272852     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunology 2004;22:329-60.
2. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263-74.
3. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic cell defects. Nat Rev Immunology 2004;4:941-52.
4. PotapenkoM, Shurin G, De Leon J. Gan- gliosides as immunomodulators. Adv Exp Med Biol 2007;601:195-203.
5. Ritter G, Livingston PO. Ganglioside antigens expressed by human cancer cells. Semin Cancer Biol 1991;2:401-9.
6. Varki A. N-glycolylneuraminic acid deficiency in humans. Biochimie 2001 ; 83:615-22.
7. Irie A, Koyama S, Kozutsumi Y, Kawasaki T, Suzuki A. The molecular basis for the absence of N-glycolylneuraminic acid in humans. J Biol Chem 1998;273: 15866-71.
8. Bardor M, Nguyen DH, Diaz S, Varki A. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem 2005;280:4228-37.
9. Yin J, Hashimoto A, Izawa M, Miyazaki K, Chen GY, Takematsu H, et al Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Research 2006; 66:2937-45.
10. Marquina G, Waki H, Fernández LE, Kon K, Carr A, Valiente O, et al Gangliosides expressed in human breast cancer. Cancer Research 1996;56:5165-71.
11. Carr A, Mullet A, Mazorra Z, Vazquez AM, Alfonso M, Mesa C, et al. A mouse IgGl monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybrido- ma 2000;19:241-7.
12. De León J, Fernández A, Mesa C, Clavell M, Fernández LE. Role of tumour- associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunology Immunotherapy 2006; 55: 443-50.
13. + regulatory T cells function. International Immunology 2008;20:591-600.
14. Gallimore A, Sakaguchi S. Regulation of tumour immunity by CD254- T cells. Immunology 2002;1:5-9.